Zydus Lifesciences Limited has informed the Exchange about Buyback
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts more than Nifty 100 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zydus Lifesciences Limited's Board has approved a buyback of up to 95,65,217 equity shares (approximately 0.95% of total paid-up capital) at INR 1,150 per share. The total buyback size is capped at INR 1,100 crores. The buyback represents 5.16% and 3.84% of standalone and consolidated free reserves respectively as of March 31, 2026, well within the statutory 10% limit. The buyback will be conducted via a tender offer route on a proportionate basis, with 15% reserved for small shareholders. ICICI Securities Limited has been appointed as the manager and buying broker. The record date for determining eligible shareholders is Friday, May 29, 2026. The buyback must be completed within one year from the board meeting date (May 19, 2026).
The buyback signals management confidence in the company's fundamentals and provides an exit opportunity to shareholders at INR 1,150 per share. It will reduce outstanding shares and is expected to support the stock price, though the actual impact depends on how the current market price compares to the buyback price.